Imlunestrant and abemaciclib for early ER+ breast cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests whether adding two targeted drugs, imlunestrant and abemaciclib, to your usual hormone therapy can lower the chance of your breast cancer coming back. It is for people with early-stage ER+ breast cancer who have no signs of cancer on scans but have tiny amounts of tumor DNA in their blood (called ctDNA).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had surgery for stage I, II, or III breast cancer that is ER-positive and HER2-negative.
- You have no evidence of cancer on physical exam or scans, but a special blood test found tiny amounts of tumor DNA (ctDNA) in the past 6 months.
- You have been on adjuvant hormone therapy (like tamoxifen or an aromatase inhibitor) for at least 2 years and are still taking it.
- You have not had a CDK 4/6 inhibitor in the last 6 months.
- You are 18 or older, with good kidney, liver, and blood counts, and able to swallow pills.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a special PET scan can predict how well the drug abemaciclib works for people with advanced hormone receptor-positive, HER2-negative breast cancer. If you qualify, you would receive abemaciclib and have imaging scans to see if your cancer responds.
This trial studies whether the combination of abemaciclib and elacestrant can slow or shrink ER-positive, HER2-negative breast cancer that has spread to the brain. It is designed for people whose cancer has progressed despite prior hormone (endocrine) treatment.
This early-phase trial tests several combinations of cancer medicines to slow or control ER-positive breast cancer that has returned or progressed. It also checks safety and whether tumor or blood biomarkers can help match the right treatment to the right person.
This trial tests a new combination of two oral medications—imlunestrant (a hormone therapy) and abemaciclib (a drug that blocks cancer growth)—given before surgery. The goal is to see if these drugs can shrink the tumor, using your tumor's growth rate (Ki67) after two weeks of treatment to guide further therapy.
This trial tests a drug called abemaciclib for people with early-stage, hormone-receptor-positive, HER2-negative breast cancer who still have cancer DNA in their blood after completing standard treatment. It aims to see if taking this drug can reduce the chance of cancer coming back.
This trial tests whether adding a targeted therapy (abemaciclib) to standard chemotherapy before surgery can shrink tumors and improve outcomes in hormone-positive, HER2-negative early breast cancer. It also uses a genetic test (Oncotype DX) to help guide surgical choices.
Hear when a new Anatomic Stage I Breast Cancer AJCC v8 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.